Jason Karlawish, professor of medicine, medical ethics, health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine and co-director of the Penn Memory Center, returned to London’s ExCeL for the 2026 Alzheimer Association International Conference. He notes that the physical setting—the Docklands trains, the ExCeL façade, and the familiar hotels and restaurants—was unchanged from his last visit in 2017. Yet what he heard and sensed at the meeting felt markedly different.
Karlawish frames his central takeaway in a single sentence: in the nine years since he last attended AAIC, the way people talk about the aging brain has been transformed. He reports that a single comment at a breakfast meeting convened by the Davos Alzheimer’s Collaborative captured that shift for him.
At the Davos-organized session, Karlawish recounts, a speaker’s remark crystallized a broader change: the conversation about Alzheimer’s disease and related conditions is taking on an economic and systems-oriented posture. The excerpt of the article available publicly quotes the Davos Alzheimer’s Collaborative describing its mission as “uniting leading organizations worldwide to build an innovation ecosystem that will accelerate breakthroughs, develop and scale promising solutions and equip every healthcare system to end Alzheimer’s disease everywhere.”
That mission statement, as presented in Karlawish’s piece, signals an emphasis on coordination, scaling, and system-level solutions—language that moves beyond individual laboratory advances to questions about delivery, financing, and the institutional structures needed to deploy new diagnostics or therapies at population scale.
Karlawish interprets the shift as more than rhetorical. He says it represents a different mindset about the aging brain: not only what science can discover, but how those discoveries can be integrated into health systems, financed, and sustained. In his view, this reframing suggests that dementia is attracting strategies and players interested in building durable infrastructure—and that this, in turn, creates a business logic around care, detection, and treatment.
Karlawish presents the change in framing as a consequential development. If dementia is now being discussed in terms of systems, scale, and markets, then conversations about access, reimbursement, care pathways, and public–private partnerships will likely become central to the field’s next phase. The Davos Alzheimer’s Collaborative’s stated objective of creating an “innovation ecosystem” illustrates the sort of cross-sector alignment—between funders, health systems, industry, and governments—that would be necessary to move promising tools from research into routine care.
The excerpt does not include the specific examples, evidence, or named initiatives Karlawish used to support his argument in full. The publicly available portion stops after setting up the argument and quoting the Davos Alzheimer’s Collaborative; the remainder of his analysis was published as STAT+ subscriber content.
The piece cites the Davos Alzheimer’s Collaborative as a five-year-old organization and reproduces its self-description. That description emphasizes global coordination and scaling of solutions. Beyond that organizational quote, the excerpt does not provide further operational details, partnerships, funding sources, or pilot programs tied to the Collaborative.
The accessible section of Karlawish’s column lays out his central observation and offers anecdotal context—his travel, the unchanged venue, and the moment at the breakfast meeting—but does not include the fuller reporting, examples, or data that would substantiate how the business model for dementia is emerging in practice. Important specifics—such as named companies, financing models, policy proposals, clinical programs, or conference presentations that illustrate this economic shift—are part of the STAT+ subscriber-only content and were not included in the public excerpt.
Readers should note that the article’s deeper analysis, the concrete instances Karlawish may have used to trace the shift from a biomedical focus to an infrastructure-driven approach, and any recommended next steps or critiques are behind the STAT+ paywall and therefore not reported here.
Karlawish writes from a position of long-standing engagement with dementia care and policy. His academic and clinical roles at the University of Pennsylvania and his leadership at the Penn Memory Center inform his reading of changes in the field. He also produces the podcast “Age of Aging,” which situates him as an observer of cultural and institutional trends in aging and brain health. Those credentials shape his interpretation of the conference dynamics he describes.
The publicly available portion of the column does not specify next steps, policy prescriptions, or the specific actors who will define the new business model for dementia. Karlawish’s characterization—that the field has moved toward a model shaped by infrastructure and economics rather than only laboratory breakthroughs—is the principal claim on the record here. Additional examples and analysis that might clarify how this model will operate, who will benefit, and what trade-offs it entails were not reported in the accessible excerpt.
Jason Karlawish’s short public excerpt from AAIC2026 conveys a clear, concise observation: the way experts and organizations now discuss the aging brain has shifted toward considerations of scale, infrastructure, and systems—elements that support the emergence of a business model for dementia. The Davos Alzheimer’s Collaborative’s stated mission serves as an emblem of that change in emphasis. The article’s in-depth reporting and specific evidence for this assertion are contained in the STAT+ subscriber-only portion and were not available in the source material provided.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.